Belantamab Mafodotin Combination Improves PFS in Relapsed or Refractory Multiple Myeloma
A phase 3 trial has shown that the combination of belantamab mafodotin, bortezomib, and dexamethasone (BVd) had a significant benefit in terms of
Multiple Myeloma
Society Updates
Guillermo Garcia-Manero, MD | SOHO President 2024
The Board of Directors and the Steering committee of the Society of Hematologic Oncology are pleased to announce that Dr. Guillermo Garcia-Manero assumed the position of SOHO